Oncology company Zentalis posts double-digit gain after pricing upsized IPO

For the handful of biotechs waiting in the IPO queue, Zentalis’ upsized offering and early aftermarket performance offer encouraging signs that the public markets remain receptive to new biopharma listings, even amid weeks of uncertainty due to the COVID-19 outbreak.

Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) gained $5.20 (29%)

Read the full 462 word article

How to gain access

Continue reading with a
two-week free trial.